|
RWDD2A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.25930385511219E-13 |
| Normal-vs-Stage2 |
5.64079999999523E-05 |
| Normal-vs-Stage3 |
1.48230316909803E-11 |
| Normal-vs-Stage4 |
7.77977682275832E-12 |
| Stage1-vs-Stage2 |
5.184200E-01 |
| Stage1-vs-Stage3 |
2.557600E-02 |
| Stage1-vs-Stage4 |
6.599600E-03 |
| Stage2-vs-Stage3 |
6.921800E-02 |
| Stage2-vs-Stage4 |
2.905500E-02 |
| Stage3-vs-Stage4 |
5.024400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.85019785550844E-11 |
| Normal-vs-AfricanAmerican |
5.86710000000101E-05 |
| Normal-vs-Asian |
1.50488999999254E-05 |
| Caucasian-vs-AfricanAmerican |
4.702600E-01 |
| Caucasian-vs-Asian |
8.364400E-03 |
| AfricanAmerican-vs-Asian |
3.323000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.86390022807836E-10 |
| Normal-vs-Female |
1.64801505775358E-12 |
| Male-vs-Female |
6.337600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.03829994286309E-10 |
| Normal-vs-Age(41-60Yrs) |
1.03640429571783E-11 |
| Normal-vs-Age(61-80Yrs) |
4.08439948529349E-11 |
| Normal-vs-Age(81-100Yrs) |
3.148000E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.175200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.079000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.389800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.350210E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.529000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.507600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.72060000000774E-06 |
| Classical-VS-Follicular |
1.808640E-01 |
| Classical-VS-Other |
3.268200E-01 |
| Classical-VS-Normal |
9.27199983458138E-10 |
| Tall-VS-Follicular |
5.6257000000004E-05 |
| Tall-VS-Other |
5.343200E-01 |
| Tall-VS-Normal |
1.64734892393881E-12 |
| Follicular-VS-Other |
3.213200E-01 |
| Follicular-VS-Normal |
3.69180000000524E-05 |
| Other-VS-Normal |
1.321000E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.04010039364755E-10 |
| Normal-vs-N1 |
7.79389885963155E-11 |
| N0-vs-N1 |
2.950200E-02 |
|
|
